IHE:NYE-iShares U.S. Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 70.01

Change

-0.14 (-0.20)%

Market Cap

N/A

Volume

0.04M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-18 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.07 (+0.05%)

USD 37.98B
FHLC Fidelity® MSCI Health Care In..

-0.08 (-0.12%)

USD 2.70B
FXH First Trust Health Care AlphaD..

-0.53 (-0.50%)

USD 1.01B
XHE SPDR® S&P Health Care Equipme..

-0.83 (-0.98%)

USD 0.18B
IDNA iShares Genomics Immunology an..

-0.47 (-2.12%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

-0.67 (-2.16%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

+0.12 (+0.12%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.32 (-1.12%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

-1.27 (-2.07%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.55 (-2.73%)

USD 6.67M

ETFs Containing IHE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.53% 81% B- 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.53% 81% B- 81% B-
Trailing 12 Months  
Capital Gain 4.27% 81% B- 58% F
Dividend Return 1.38% 94% A 26% F
Total Return 5.66% 86% B+ 51% F
Trailing 5 Years  
Capital Gain 67.45% 62% D 52% F
Dividend Return 11.32% 95% A 21% F
Total Return 78.77% 71% C- 44% F
Average Annual (5 Year Horizon)  
Capital Gain 3.92% 48% F 47% F
Dividend Return 5.31% 57% F 44% F
Total Return 1.40% 100% F 33% F
Risk Return Profile  
Volatility (Standard Deviation) 15.23% 71% C- 66% D+
Risk Adjusted Return 34.87% 67% D+ 49% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike